Visualant and BIOMEDX Sign Joint Development Agreement

Focus on ChromaID to Aid in Enhanced 3-D and Holographic Imaging for Certain Medical Procedures

SEATTLE--()--Visualant, Inc. (OTCQB: VSUL) – a photonics technology development company providing chromatic-based identification, authentication and diagnostic solutions, with its ChromaID™ technology, announced today that it has entered into a Joint Development Agreement with BIOMEDX Group, Inc., to develop its ChromaID technology as an exclusive analytical photonic tool for Aesthetics, Dermatology and Plastic Surgery.

The BIOMEDX Group, Inc. is a technology company founded to develop and commercialize photo-realistic 3-D and holographic digital human modeling for the medical/healthcare industry. The Company is developing specialized, interactive applications for simulation programs to capture real-time, pre-procedural modeling of facial cosmetic and reconstructive surgical methods including computer generated human anatomy to display holographic physiologically accurate simulations of the human body, including the biometrics of actual tissue and organs. Visualant and BIOMEDX will be developing applications using Visualant’s photonic ChromaID technology to analyze and determine various characteristics of the skin and underlying subdermal tissue as it relates BIOMEDX enhanced 3-D and holographic imaging for dermatologic, plastic surgery and aesthetic applications, a multi-billion dollar global market.

BIOMEDX Group, Inc. is led by Rudy Mazzocchi, an internationally renowned biomedical and technology entrepreneur. Mazzocchi is also Executive Chairman of Establishment Labs, a global aesthetic company, and Executive Chairman of LAFORGE Optical, a heads-up display eyewear company. The medical/technology team at BIOMEDX includes Dr. Raghu Raghavan, former Professor of Computer Science & Radiology at Johns Hopkins University and an author of over 150 Research Publication and 37 Patents as its Chief Technical Officer; and Goal Chopra, MD, MBA, a Neurosurgeon, Ophthalmologist and entrepreneur, who holds a faculty position in Dept. of Human Anatomical Studies at Stanford University, and a former Investment Banker at Lazard and Business Development Director of Boston Scientific Corporation, as its Chief Medical Officer.

We are very excited to work with Visualant to jointly develop and deploy their ChromaID technology into the medical/healthcare marketplace through our existing channel relationships,” stated Mazzocchi, BIOMEDX Chairman and Acting-CEO. “We believe this Joint Development undertaking will lead to advancing the ChromaID technology not only in these addressable markets but also other large global markets for the ChromaID technology.”

Rudy Mazzocchi and his team have a deep and proven understanding of the biomedical marketplace and the opportunities it provides for our technology,” said Visualant CEO, President and Founder, Ron Erickson. “We are very excited to work with BIOMEDX through this Joint Development Agreement, as it expands the opportunities for us to not only develop our technology but also deploy our technology in the biomedical and med-tech global markets. We intend to become a leader in utilizing photonic technology in this and other important market segments.”

About Visualant, Inc.

Visualant™ is a public company whose shares trade under the stock symbol “VSUL.” The Visualant Spectral Pattern Matching™ (SPM) technology directs structured light onto a substance or material, through a liquid or gas, or off a surface, to capture a unique ChromaID™. A ChromaID can be used to identify, detect, or diagnosis markers invisible to the human eye. ChromaID scanner modules can be integrated into a variety of mobile or fixed-mount form factors. The patented, award-winning photonics technology is disruptive, making it possible to effectively conduct analyses in the field that could only previously be performed by large and expensive lab-based tests. For more information on Visualant, visit the company’s website at www.visualant.net.

About BIOMEDX Group Inc.

The BIOMEDX Group is a private company, that has an exclusive worldwide license from PULSE Evolution, Inc, world leaders in holographic content for use in film and entertainment, for all applications in medicine and healthcare, with an initial product development focus on the modeling and simulation of the human face for aesthetic and facial reconstruction applications.

Contacts

Visualant Contact:
Redwood Investment Group
Div of: Pillar Marketing Group, Inc
Tom Hemingway, 714-978-4425
or
BIOMEDX Contact:
Rudy Mazzocchi, 321-229-2014

Contacts

Visualant Contact:
Redwood Investment Group
Div of: Pillar Marketing Group, Inc
Tom Hemingway, 714-978-4425
or
BIOMEDX Contact:
Rudy Mazzocchi, 321-229-2014